• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可溶性白细胞介素-2受体、肿瘤坏死因子-α和超敏C反应蛋白水平升高是非ST段抬高型急性冠脉综合征患者经皮冠状动脉介入治疗后冠状动脉慢血流的独立危险因素。

Elevated levels of sIL-2R, TNF-α and hs-CRP are independent risk factors for post percutaneous coronary intervention coronary slow flow in patients with non-ST segment elevation acute coronary syndrome.

作者信息

Wang Cheng, Wu Yan, Su Yang, Mao Bin, Luo Yihong, Yan Yexiang, Hu Kun, Lu Yi, Che Wenliang, Wan Minying

机构信息

Department of Cardiology, Chongming Branch, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 66 East Xiangyang Road, Chongming, Shanghai, China.

Department of Cardiology, Shanghai Putuo District Liqun Hospital, Shanghai, 200333, China.

出版信息

Int J Cardiovasc Imaging. 2022 Jun;38(6):1191-1202. doi: 10.1007/s10554-022-02529-8. Epub 2022 Feb 19.

DOI:10.1007/s10554-022-02529-8
PMID:35182256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11143008/
Abstract

To evaluate the association between circulating levels of inflammatory cytokines and the occurrence of post-percutaneous coronary intervention (PCI) coronary slow flow (CSF) in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS). CSF after PCI commonly occurs and implies poor outcomes, while the determinants of post-PCI CSF in patients with NSTE-ACS remain controversial. In this multicenter case control study, 176 patients diagnosed with NSTE-ACS and with post-PCI CSF occurred composed of CSF group, while 352 matched NSTE-ACS patients composed control group. Corrected thrombolysis in myocardial infarction frame count (cTFC), circulating levels of inflammatory cytokines and PCI related parameters were analyzed using Logistic regression models. Among 528 patients with median age of 67 (59-76) and male proportion of 65.5%, 176 (35.0%) patients had occurrence of post-PCI CSF defined as cTFC ≥ 24. Patients with CSF presented more intense inflammatory activity revealed by higher levels of white blood cell, high-sensitivity C-reactive protein (hs-CRP), interleukin-1ß (IL-1ß), soluble IL-2 receptor (sIL-2R), IL-6, IL-8, IL-10 and tumor necrosis factor-α (TNF-α), while PCI related parameters were comparable. Correlation analysis showed cTFC was positively correlated with those inflammatory cytokines. Logistic regression model indicates that hs-CRP (odds ratio (OR) = 3.038, 95% confidence interval (CI) 1.545-5.975), sIL-2R (OR = 2.103, 95% CI 1.959-4.026) and TNF-α (OR = 3.708, 95% CI 1.426-9.641) were valuable predictors for CSF occurrence. Elevated circulating levels of inflammatory cytokine including hs-CRP, sIL-2R and TNF-α rather than PCI related parameters could predict post-PCI CSF in patients with NSTE-ACS.

摘要

评估非ST段抬高型急性冠脉综合征(NSTE-ACS)患者经皮冠状动脉介入治疗(PCI)后冠状动脉慢血流(CSF)的发生与循环炎症细胞因子水平之间的关联。PCI术后CSF较为常见且提示预后不良,而NSTE-ACS患者PCI术后CSF的决定因素仍存在争议。在这项多中心病例对照研究中,176例诊断为NSTE-ACS且发生PCI术后CSF的患者组成CSF组,352例匹配的NSTE-ACS患者组成对照组。使用Logistic回归模型分析校正的心肌梗死溶栓帧数(cTFC)、循环炎症细胞因子水平和PCI相关参数。在528例中位年龄为67岁(59-76岁)且男性比例为65.5%的患者中,176例(35.0%)患者发生了定义为cTFC≥24的PCI术后CSF。CSF患者表现出更强烈的炎症活动,表现为白细胞、高敏C反应蛋白(hs-CRP)、白细胞介素-1β(IL-1β)、可溶性IL-2受体(sIL-2R)、IL-6、IL-8、IL-10和肿瘤坏死因子-α(TNF-α)水平更高,而PCI相关参数相当。相关性分析显示cTFC与这些炎症细胞因子呈正相关。Logistic回归模型表明,hs-CRP(比值比(OR)=3.038,95%置信区间(CI)1.545-5.975)、sIL-2R(OR=2.103,95%CI 1.959-4.026)和TNF-α(OR=3.708,95%CI 1.426-9.641)是CSF发生的有价值预测指标。包括hs-CRP、sIL-2R和TNF-α在内的循环炎症细胞因子水平升高而非PCI相关参数可预测NSTE-ACS患者PCI术后CSF。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b1/11143008/82034795cee0/10554_2022_2529_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b1/11143008/f78d291255a6/10554_2022_2529_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b1/11143008/96118acc23e7/10554_2022_2529_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b1/11143008/82034795cee0/10554_2022_2529_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b1/11143008/f78d291255a6/10554_2022_2529_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b1/11143008/96118acc23e7/10554_2022_2529_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b1/11143008/82034795cee0/10554_2022_2529_Fig3_HTML.jpg

相似文献

1
Elevated levels of sIL-2R, TNF-α and hs-CRP are independent risk factors for post percutaneous coronary intervention coronary slow flow in patients with non-ST segment elevation acute coronary syndrome.可溶性白细胞介素-2受体、肿瘤坏死因子-α和超敏C反应蛋白水平升高是非ST段抬高型急性冠脉综合征患者经皮冠状动脉介入治疗后冠状动脉慢血流的独立危险因素。
Int J Cardiovasc Imaging. 2022 Jun;38(6):1191-1202. doi: 10.1007/s10554-022-02529-8. Epub 2022 Feb 19.
2
Impact of persistent subclinical hypothyroidism on clinical outcomes in non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention.经皮冠状动脉介入治疗的非 ST 段抬高急性冠状动脉综合征患者亚临床甲状腺功能减退持续状态对临床结局的影响。
Clin Endocrinol (Oxf). 2022 Jan;96(1):70-81. doi: 10.1111/cen.14613. Epub 2021 Oct 12.
3
Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial.非 ST 段抬高型心肌梗死患者经皮冠状动脉介入治疗中冠状动脉操作并发症的流行情况、临床决定因素及预后意义:来自当代多国 TAO 试验的结果。
Arch Cardiovasc Dis. 2021 Mar;114(3):187-196. doi: 10.1016/j.acvd.2020.09.005. Epub 2021 Jan 29.
4
Unraveling the rapid progression of non-target lesions: risk factors and the therapeutic potential of PCSK9 inhibitors in post-PCI patients.解析非靶病变的快速进展:PCI 后患者 PCSK9 抑制剂的风险因素和治疗潜力。
BMC Cardiovasc Disord. 2024 Sep 18;24(1):499. doi: 10.1186/s12872-024-04186-2.
5
C-reactive protein and uric acid roles in distinguishing ST-segment elevation myocardial infarction from non-ST-elevation acute coronary syndrome.C反应蛋白和尿酸在区分ST段抬高型心肌梗死与非ST段抬高型急性冠状动脉综合征中的作用。
J Immunoassay Immunochem. 2023 Jan 2;44(1):66-75. doi: 10.1080/15321819.2022.2119866. Epub 2022 Sep 8.
6
Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome.急性冠状动脉综合征患者行全剂量或低剂量比伐芦定术后输注。
J Am Coll Cardiol. 2019 Feb 26;73(7):758-774. doi: 10.1016/j.jacc.2018.12.023.
7
Occlusion of the infarct-related coronary artery presenting as acute coronary syndrome with and without ST-elevation: impact of inflammation and outcomes in a real-world prospective cohort.梗死相关动脉闭塞导致的急性冠状动脉综合征伴或不伴 ST 段抬高:炎症和预后的影响,一项真实世界前瞻性队列研究。
Eur Heart J Qual Care Clin Outcomes. 2023 Sep 12;9(6):564-574. doi: 10.1093/ehjqcco/qcad027.
8
Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction.稳定性缺血性心脏病、非ST段抬高型急性冠状动脉综合征和ST段抬高型心肌梗死患者复发性缺血事件的风险及发生时间。
Am Heart J. 2016 May;175:56-65. doi: 10.1016/j.ahj.2016.01.021. Epub 2016 Feb 23.
9
Coronary lipid-rich plaque characteristics in Japanese patients with acute coronary syndrome and stable angina: A near infrared spectroscopy and intravascular ultrasound study.日本急性冠状动脉综合征和稳定型心绞痛患者的冠状动脉富脂斑块特征:一项近红外光谱和血管内超声研究。
Int J Cardiol Heart Vasc. 2021 Mar 11;33:100747. doi: 10.1016/j.ijcha.2021.100747. eCollection 2021 Apr.
10
Tissue characteristics of culprit lesion and myocardial tissue-level perfusion in non-ST-segment elevation acute coronary syndromes: The EARLY-MYO-ACS study.非 ST 段抬高型急性冠状动脉综合征罪犯病变组织特征与心肌组织水平灌注:EARLY-MYO-ACS 研究。
Int J Cardiol. 2019 Jul 15;287:32-38. doi: 10.1016/j.ijcard.2019.02.010. Epub 2019 Feb 8.

引用本文的文献

1
The relationship between neutrophil percentage-to-albumin ratio and slow and normal coronary flow phenomenon.中性粒细胞百分比与白蛋白比值和冠状动脉血流缓慢及正常现象之间的关系。
BMC Cardiovasc Disord. 2025 Jan 31;25(1):64. doi: 10.1186/s12872-025-04507-z.
2
Determining the association of inflammatory markers, cell-adhesion molecules, and endothelial dysfunction biomarkers with ACS in Indian population.确定印度人群中炎症标志物、细胞粘附分子和内皮功能障碍生物标志物与急性冠状动脉综合征(ACS)之间的关联。
Indian Heart J. 2024 Jan-Feb;76(1):63-66. doi: 10.1016/j.ihj.2024.01.016. Epub 2024 Jan 30.
3
Advances in cardiovascular-related biomarkers to predict diabetic peripheral neuropathy.

本文引用的文献

1
Comparative Effectiveness of Anti-Inflammatory Drug Treatments in Coronary Heart Disease Patients: A Systematic Review and Network Meta-Analysis.抗炎症药物治疗在冠心病患者中的比较效果:系统评价和网络荟萃分析。
Mediators Inflamm. 2021 Jan 14;2021:5160728. doi: 10.1155/2021/5160728. eCollection 2021.
2
Association Between Primary Coronary Slow-Flow Phenomenon and Epicardial Fat Tissue.原发性冠状动脉慢血流现象与心外膜脂肪组织的关系。
J Invasive Cardiol. 2021 Jan;33(1):E59-E64. doi: 10.25270/jic/20.00294.
3
Elevated Lipoprotein-Associated Phospholipase A2 is Valuable in Prediction of Coronary Slow Flow in Non-ST-Segment Elevation Myocardial Infarction Patients.
预测糖尿病周围神经病变的心血管相关生物标志物研究进展
World J Diabetes. 2023 Aug 15;14(8):1226-1233. doi: 10.4239/wjd.v14.i8.1226.
脂蛋白相关磷脂酶 A2 水平升高对非 ST 段抬高型心肌梗死患者冠状动脉慢血流有预测价值。
Curr Probl Cardiol. 2021 Mar;46(3):100596. doi: 10.1016/j.cpcardiol.2020.100596. Epub 2020 Apr 17.
4
Plasma Choline as a Diagnostic Biomarker in Slow Coronary Flow.血浆胆碱作为冠状动脉血流缓慢的诊断生物标志物
Cardiol Res Pract. 2020 Jan 25;2020:7361434. doi: 10.1155/2020/7361434. eCollection 2020.
5
Association between the No-Reflow Phenomenon and Soluble CD40 Ligand Level in Patients with Acute ST-Segment Elevation Myocardial Infarction.急性 ST 段抬高型心肌梗死患者无复流现象与可溶性 CD40 配体水平的相关性。
Medicina (Kaunas). 2019 Jul 15;55(7):376. doi: 10.3390/medicina55070376.
6
[Can biomarkers help us to understand the pathogenesis of coronary slow flow? Endocan and omentin-I in slow coronary flow phenomenon].[生物标志物能帮助我们理解冠状动脉慢血流的发病机制吗?内脂素和网膜素-1与冠状动脉慢血流现象]
Turk Kardiyol Dern Ars. 2019 Jun;47(4):251-257. doi: 10.5543/tkda.2018.27708.
7
Correlation IMA with TIMI frame count in slow coronary flow: can it be a guide for treatment?冠状动脉慢血流中缺血修饰白蛋白(IMA)与心肌梗死溶栓治疗(TIMI)帧数的相关性:它能否作为治疗的指导指标?
Aging Male. 2020 Dec;23(5):635-640. doi: 10.1080/13685538.2018.1561842. Epub 2019 Feb 10.
8
The Role of Colchicine in Acute Coronary Syndromes.秋水仙碱在急性冠状动脉综合征中的作用。
Clin Ther. 2019 Jan;41(1):11-20. doi: 10.1016/j.clinthera.2018.07.023. Epub 2018 Sep 2.
9
Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).白介素-6 信号通路的调节与动脉粥样硬化事件和全因死亡率的发生率:来自卡那单抗抗炎血栓形成结局研究(CANTOS)的分析。
Eur Heart J. 2018 Oct 7;39(38):3499-3507. doi: 10.1093/eurheartj/ehy310.
10
Integrated proteomic analysis of tumor necrosis factor α and interleukin 1β-induced endothelial inflammation.肿瘤坏死因子-α和白细胞介素 1β诱导的内皮炎症的综合蛋白质组学分析。
J Proteomics. 2019 Feb 10;192:89-101. doi: 10.1016/j.jprot.2018.08.011. Epub 2018 Aug 25.